The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium

详细信息    查看全文

• 作者：Neil M. Davies ; Tom R. Gaunt ; Sarah J. Lewis ; Jeff Holly…
• 关键词：Height ; Body mass index ; Prostate cancer ; Mendelian randomization ; Single nucleotide polymorphisms ; Instrumental variables analysis
• 刊名：Cancer Causes & Control
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：26
• 期：11
• 页码：1603-1616
• 全文大小：504 KB
• 参考文献：1.Gr枚nberg H (2003) Prostate cancer epidemiology. Lancet Lond Engl 361:859鈥?64CrossRef r>2.Discacciati A, Orsini N, Wolk A (2012) Body mass index and incidence of localized and advanced prostate cancer: a dose鈥搑esponse meta-analysis of prospective studies. Ann Oncol 23:1665鈥?671CrossRef PubMed r>3.Cao Y, Ma J (2011) Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res 4:486鈥?01CrossRef r>4.Discacciati A et al (2011) Body mass index in early and middle-late adulthood and risk of localised, advanced and fatal prostate cancer: a population-based prospective study. Br J Cancer 105:1061鈥?068PubMed Central CrossRef PubMed r>5.MacInnis RJ, English DR (2006) Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control CCC 17:989鈥?003CrossRef PubMed r>6.Zuccolo L et al (2008) Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis. Cancer Epidemiol Biomark Prev 17:2325鈥?336CrossRef r>7.Littman AJ, White E, Kristal AR (2007) Anthropometrics and prostate cancer risk. Am J Epidemiol 165:1271鈥?279CrossRef PubMed r>8.Freedland SJ, Platz EA (2007) Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 29:88鈥?7CrossRef PubMed r>9.Buschemeyer WC, Freedland SJ (2007) Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 52:331鈥?43CrossRef PubMed r>10.Gong Z et al (2006) Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomark Prev 15:1977鈥?983CrossRef r>11.Collaboration Emerging Risk Factors (2012) Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis. Int J Epidemiol 41:1419鈥?433CrossRef r>12.Epstein MM et al (2012) Dietary fatty acid intake and prostate cancer survival in 脰rebro County, Sweden. Am J Epidemiol 176:240鈥?52PubMed Central CrossRef PubMed r>13.Rowlands M-A et al (2012) Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case鈥揷ontrol study ProtecT. Cancer Res 72:503鈥?15PubMed Central CrossRef PubMed r>14.Rowlands M-A et al (2010) The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study. Cancer Causes Control CCC 21:1829鈥?842CrossRef PubMed r>15.Lewis SJ et al (2010) Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk. PLoS One 5:e13485PubMed Central CrossRef PubMed r>16.Gunnell DJ, Smith GD, Frankel SJ, Kemp M, Peters TJ (1998) Socio-economic and dietary influences on leg length and trunk length in childhood: a reanalysis of the Carnegie (Boyd Orr) survey of diet and health in prewar Britain (1937鈥?9). Paediatr Perinat Epidemiol 12(Suppl 1):96鈥?13CrossRef PubMed r>17.Gunnell D et al (2001) Height, leg length, and cancer risk: a systematic review. Epidemiol Rev 23:313鈥?42CrossRef PubMed r>18.Gunnell D (2002) Can adult anthropometry be used as a 鈥渂iomarker鈥?for prenatal and childhood exposures? Int J Epidemiol 31:390鈥?94CrossRef PubMed r>19.Davey Smith G, Ebrahim S (2003) Mendelian randomization: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32:1鈥?2CrossRef r>20.Davey Smith G, Hemani G (2014) Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 23:R89鈥揜98PubMed Central CrossRef PubMed r>21.Palmer TM et al (2012) Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res 21:223鈥?42PubMed Central CrossRef PubMed r>22.Burgess S, Thompson SG (2013) Use of allele scores as instrumental variables for Mendelian randomization. Int J Epidemiol 42:1134鈥?144PubMed Central CrossRef PubMed r>23.Lango Allen H et al (2010) Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 467:832鈥?38PubMed Central CrossRef PubMed r>24.Speliotes EK et al (2010) Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 42:937鈥?48PubMed Central CrossRef PubMed r>25.Kote-Jarai Z et al (2008) Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomark Prev 17:2052鈥?061CrossRef r>26.Eeles RA et al (2013) Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 45:385鈥?91CrossRef PubMed r>27.Howie BN, Donnelly P, Marchini J (2009) A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 5:e1000529PubMed Central CrossRef PubMed r>28.Lane JA et al (2010) Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer 46:3095鈥?101CrossRef PubMed r>29.Burgess S (2014) Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome. Int J Epidemiol 43:922鈥?29PubMed Central CrossRef PubMed r>30.Collin SM et al (2008) Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case鈥揷ontrol study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. BJU Int 102:1400鈥?406PubMed r>31.Didelez V, Sheehan N (2007) Mendelian randomization as an instrumental variable approach to causal inference. Stat Methods Med Res 16:309鈥?30CrossRef PubMed r>32.VanderWeele TJ, Tchetgen Tchetgen EJ, Cornelis M, Kraft P (2014) Methodological challenges in Mendelian randomization. Epidemiology 25:427鈥?35PubMed Central CrossRef PubMed r>33.Altman DG, Bland JM (2003) Statistics Notes: interaction revisited: the difference between two estimates. Br Med J 326:219CrossRef r>34.Evans DM et al (2013) Mining the human phenome using allelic scores that index biological intermediates. PLoS Genet 9:e1003919PubMed Central CrossRef PubMed r>35.Davey Smith G (2011) Use of genetic markers and gene鈥揹iet interactions for interrogating population-level causal influences of diet on health. Genes Nutr 6:27鈥?3PubMed Central CrossRef PubMed r>36.Edwards TL, Giri A, Motley S, Duong W, Fowke JH (2013) Pleiotropy between genetic markers of obesity and risk of prostate cancer. Cancer Epidemiol Biomark Prev 22:1538鈥?546CrossRef r>37.Sutcliffe S, Colditz GA (2013) Prostate cancer: is it time to expand the research focus to early-life exposures? Nat Rev Cancer 13:208鈥?18PubMed Central CrossRef PubMed r>38.Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC (1997) Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomark Prev 6:557鈥?63 r>39.Gunnell D et al (2004) Do height-related variations in insulin-like growth factors underlie the associations of stature with adult chronic disease? J Clin Endocrinol Metab 89:213鈥?18CrossRef PubMed r>40.Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625鈥?638CrossRef PubMed r>41.Rodriguez C et al (2001) Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomark Prev 10:345鈥?53 r>42.Freeman VL, Liao Y, Durazo-Arvizu R, Cooper RS (2001) Height and risk of fatal prostate cancer: findings from the National Health Interview Survey (1986 to 1994). Ann Epidemiol 11:22鈥?7CrossRef PubMed r>43.Chen H, Miller BA, Giovannucci E, Hayes RB (2003) Height and the survival of prostate cancer patients. Cancer Epidemiol Biomark Prev 12:215鈥?18r>44.Rowlands M-A et al (2012) Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer. Cancer Causes Control CCC 23:347鈥?54CrossRef PubMed r>45.W眉rtz P et al (2013) Lipoprotein subclass profiling reveals pleiotropy in the genetic variants of lipid risk factors for coronary heart disease: a note on Mendelian randomization studies. J Am Coll Cardiol 62:1906鈥?908CrossRef PubMed r>46.Nelson CP et al (2015) Genetically determined height and coronary artery disease. N Engl J Med 372:1608鈥?618CrossRef PubMed r>47.von Hinke Kessler Scholder S, Davey Smith G, Lawlor DA, Propper C, Windmeijer F (2012) The effect of fat mass on educational attainment: examining the sensitivity to different identification strategies. Econ Hum Biol 10:405鈥?18PubMed Central CrossRef PubMed r>48.von Hinke Kessler Scholder S, Davey Smith G, Lawlor DA, Propper C, Windmeijer F (2013) Child height, health and human capital: evidence using genetic markers. Eur Econ Rev 57:1鈥?2CrossRef r>49.Nordestgaard BG et al (2012) The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach. PLoS Med 9:e1001212PubMed Central CrossRef PubMed r>50.Fowke JH, Motley S, Dai Q, Concepcion R, Barocas DA (2013) Association between biomarkers of obesity and risk of high-grade prostatic intraepithelial neoplasia and prostate cancer-evidence of effect modification by prostate size. Cancer Lett 328:345鈥?52PubMed Central CrossRef PubMed r>
• 作者单位：Neil M. Davies (1) (2) r> Tom R. Gaunt (1) (2) r> Sarah J. Lewis (1) (2) r> Jeff Holly (3) r> Jenny L. Donovan (1) r> Freddie C. Hamdy (4) r> John P. Kemp (2) (5) r> Rosalind Eeles (6) (7) r> Doug Easton (8) r> Zsofia Kote-Jarai (6) r> Ali Amin Al Olama (8) r> Sara Benlloch (8) r> Kenneth Muir (9) r> Graham G. Giles (10) (11) r> Fredrik Wiklund (12) r> Henrik Gronberg (12) r> Christopher A. Haiman (13) r> Johanna Schleutker (14) (15) r> B酶rge G. Nordestgaard (16) r> Ruth C. Travis (17) r> David Neal (18) (19) r> Nora Pashayan (20) (41) r> Kay-Tee Khaw (21) r> Janet L. Stanford (22) (23) r> William J. Blot (24) r> Stephen Thibodeau (25) r> Christiane Maier (26) (27) r> Adam S. Kibel (28) (29) r> Cezary Cybulski (30) r> Lisa Cannon-Albright (31) r> Hermann Brenner (32) (33) (34) r> Jong Park (35) r> Radka Kaneva (36) r> Jyotsna Batra (37) r> Manuel R. Teixeira (38) (39) r> Hardev Pandha (40) r> Mark Lathrop (42) (43) r> George Davey Smith (1) (2) r> Richard M. Martin (1) (2) (44) r> PRACTICAL consortium r>r>1. School of Social and Community Medicine, University of Bristol, Bristol, UK r> 2. MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK r> 3. School of Clinical Sciences, University of Bristol, Bristol, BS10 5NB, UK r> 4. Nuffield Department of Surgery, University of Oxford, Oxford, UK r> 5. University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD, Australia r> 6. The Institute of Cancer Research, London, SM2 5NG, UK r> 7. The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK r> 8. Strangeways Laboratory, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge, UK r> 9. Institute of Population Health, University of Manchester, Manchester, UK r> 10. Cancer Epidemiology Centre, The Cancer Council Victoria, 615 St Kilda Road, Melbourne, VIC, Australia r> 11. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia r> 12. Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden r> 13. Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA r> 14. Department of Medical Biochemistry and Genetics, University of Turku, Turku, Finland r> 15. Institute of Biomedical Technology/BioMediTech, University of Tampere and FimLab Laboratories, Tampere, Finland r> 16. Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, 2730, Herlev, Denmark r> 17. Cancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK r> 18. Surgical Oncology (Uro-Oncology: S4), University of Cambridge, Addenbrooke鈥檚 Hospital, Hills Road, Box 279, Cambridge, UK r> 19. Li Ka Shing Centre, Cancer Research UK Cambridge Research Institute, Cambridge, UK r> 20. Strangeways Laboratory, Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Worts Causeway, Cambridge, UK r> 41. Department of Applied Health Research, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK r> 21. Cambridge Institute of Public Health, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 0SR, UK r> 22. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA r> 23. Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA r> 24. International Epidemiology Institute, 1455 Research Blvd., Suite 550, Rockville, MD, 20850, USA r> 25. Mayo Clinic, Rochester, MN, USA r> 26. Department of Urology, University Hospital Ulm, Ulm, Germany r> 27. Institute of Human Genetics, University Hospital Ulm, Ulm, Germany r> 28. Brigham and Women鈥檚 Hospital/Dana-Farber Cancer Institute, 45 Francis Street-ASB II-3, Boston, MA, 02115, USA r> 29. Washington University, St. Louis, Missouri r> 30. International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland r> 31. Division of Genetic Epidemiology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA r> 32. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany r> 33. Division of Preventive Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany r> 34. German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany r> 35. Division of Cancer Prevention and Control, H. Lee Moffitt Cancer Center, 12902 Magnolia Dr., Tampa, FL, USA r> 36. Molecular Medicine Center and Department of Medical Chemistry and Biochemistry, Medical University Sofia, 2 Zdrave St, 1431, Sofia, Bulgaria r> 37. Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia r> 38. Department of Genetics, Portuguese Oncology Institute, Porto, Portugal r> 39. Biomedical Sciences Institute (ICBAS), Porto University, Porto, Portugal r> 40. The University of Surrey, Guildford, Surrey, GU2 7XH, UK r> 42. Commissariat 脿 l鈥橢nergie Atomique, Center National de G茅notypage, Evry, France r> 43. McGill University-G茅nome Qu茅bec Innovation Centre, Montreal, Canada r> 44. Bristol Nutrition Biomedical Research Unit, National Institute for Health Research, Bristol, UK r>
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Healthr>Oncologyr>Cancer Researchr>Public Healthr>Epidemiologyr>Hematologyr>
• 出版者：Springer Netherlands
• ISSN：1573-7225

文摘

Background Epidemiological studies suggest a potential role for obesity and determinants of adult stature in prostate cancer risk and mortality, but the relationships described in the literature are complex. To address uncertainty over the causal nature of previous observational findings, we investigated associations of height- and adiposity-related genetic variants with prostate cancer risk and mortality.